MDT-AP-2407
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 0.96
- os_event
- false
- age_years
- 6
- new_clusters
- C3
- umap1_2d
- 6.355427024
- umap2_2d
- 4.285137938
- umap1_3d
- 2.649970208
- umap2_3d
- -0.937980091
- umap3_3d
- -1.677241878
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.280
- HEDGEHOG_SIGNALING+0.180
- KRAS_SIGNALING_DN+0.140
- SPERMATOGENESIS+0.110
- DNA_REPAIR+0.090
- HEME_METABOLISM+0.090
- ADIPOGENESIS+0.080
- GLYCOLYSIS+0.050
- XENOBIOTIC_METABOLISM+0.050
- PROTEIN_SECRETION+0.030
Top 10 suppressed
- G2M_CHECKPOINT-0.480
- E2F_TARGETS-0.460
- INTERFERON_ALPHA_RESPONSE-0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- ANDROGEN_RESPONSE-0.360
- MYC_TARGETS_V1-0.360
- MYC_TARGETS_V2-0.340
- APOPTOSIS-0.330
- MITOTIC_SPINDLE-0.330
- INTERFERON_GAMMA_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1260 | Med | Medulloblastoma | 0.892 |
| 2 | SRR1446092 | GTEX | — | 0.890 |
| 3 | SRR1435536 | GTEX | — | 0.853 |
| 4 | MDT-AP-2024 | Med | Medulloblastoma | 0.851 |
| 5 | MDT-AP-2859 | Med | Medulloblastoma | 0.848 |
| 6 | TCGA-E9-A245-01A-22R-A16F-07 | — | B | 0.846 |
| 7 | MDT-AP-1160 | Med | Medulloblastoma | 0.844 |
| 8 | TCGA-A2-A4S0-01A-21R-A266-07 | — | B | 0.843 |
| 9 | TCGA-37-4129-01A-01R-1100-07 | — | cohortSC | 0.842 |
| 10 | MNG1015 | — | — | 0.839 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.090 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.050 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.030 | Remibrutinib | — uncovered |